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PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis
We read the interesting article by Musso et al 1 concerning a case of Crohn's disease with a 3 year complete treatment-free remission after unmanipulated autologous stem cell transplantation performed for relapsed extranodal Hodgkin's lymphoma.
Allogeneic transplantation is commonly performed for haematological malignancies, and allows observation of patients with IBD who appear to enter long-term remission after transplantation. With a lower transplant-related mortality, PBSC autotransplant has been reported to be feasible and to improve the natural history of severe autoimmune diseases in some case reports. 2 Two cases of clinical remission of Crohn's disease with 7 and 3 years follow-up after PBSC autotransplant for a coincidental malignancy have been reported. One case with ulcerative colitis (UC) undergoing a PBSC autotransplant for a high-risk breast cancer has been reported. 3 This patient had mild left-sided inflammation in the pretransplant colonoscopy and was asymptomatic, off medication 2 years after transplant. At our institution we have had a recent experience concerning a patient diagnosed with UC.
In 1995, a 57-year-old woman with a 7 year history of distal UC (diagnosed by colonoscopy-guided mucosal biopsy) that required maintenance therapy with oral mesalazine (1500 mg/day) and frequent courses of corticosteroid and mesalazine enemas when episodes of acute haemorragic diarrhea occurred, was diagnosed with an infiltrating ductal carcinoma of her right breast. By this time she was on treatment with oral mesalazine (2000 mg/day) and topical mesalazine and corticosteroids for a haemorragic exacerbation. After radical mastectomy, pathology disclosed a high-risk carcinoma (48 of 49 axillary lymph nodes were positive for tumour cells). As adjuvant treatment the patient underwent three courses of chemotherapy (fluorouracil 600, epirubicin 75, cyclophosphamide 600, all expressed as mg/m 2 i.v. on day 1 of a 21-day cycle), during which the haemorragic flare-up resolved, followed by mobilisation with cyclophosphamide (4 g/m 2 ) and G-CSF for an unmanipulated PBSC autotransplant. Conditioning chemotherapy consisted of carboplatin, thiotepa and cyclophosphamide. 4 By this time the patient had no symptoms relating to IBD. 7 × 10 6 /kg CD34 cells were infused on day 0. A neutrophil count above 0.5 × 10 9 /l and platelets count above 20 × 10 9 /l were both reached on day 10. Tolerance of the transplant was good with no bowel toxicity. As the patient remained asymptomatic, mesalazine maintenance therapy was discontinued 6 months after transplant. No colonoscopy was performed for follow-up but a scintigraphy with radiolabelled leucocytes performed 14 months after transplant showed no evidence of inflammatory activity. After 25 months follow-up with no evidence of relapse of either disease the patient developed rectal bleeding again. A further scintigraph with radiolabelled leucocytes, and a colonoscopy with mucosal biopsy confirmed relapse of the UC. The patient recommenced maintenance mesalazine. The frequency and intensity of the exacerbations did not improve, so oral azathioprine was added, after which the number of flare-ups decreased progressively. The patient is now asymptomatic, and tumour free, on azathioprine, 36 months after relapse of UC.
The chemotherapy regimen used for this patient was more myeloablative than immunoablative, but no acute or delayed toxicity relating to the immunosuppression occurred. As with all patients undergoing PBSC autotransplantation at our centre, a peripheral immunologic followup (immunoglobulins, CD3, CD4, CD8, CD19 lymphocytes and NK cells) was performed every 3 months for the first 2 years after transplant and every 6 months thereafter. CD19 and NK cell recovery occurred within 6 months after transplant. Normal levels of CD3 were reached 12 months after transplant. The CD4 count and CD4/CD8 ratio decreased markedly following high-dose chemotherapy, and remained low even after relapse of the UC. In contrast, the reduction of IgG levels noted in our case after high-dose chemotherapy was followed by recovery, reaching normal levels after relapse (Figure 1) .
It is certain that high-dose chemotherapy with haematopoietic stem cell transplantation is feasible for patients with IBD, and the cases reported suggest that it may be of value in the management of patients with severe disease, but there is not enough evidence to consider this treatment outside co-operative multidisciplinary investigational protocols. Whereas the fact that some patients with severe IBD may enter long-lasting remissions, and show improved response to standard therapy even in the case of relapse as has been reported for rheumatoid arthritis is of uppermost interest, caution is needed before extending this approach to the general population of patients with severe autoimmune dis- eases such as IBD. Practical and ethical issues of PBSC transplantation in this setting have been discussed in a recent article. 5 A substantial but temporary benefit was obtained for our patient and probably, as Musso suggests, better outcome rates with less toxicity may be reached with more immunoablative regimens, such as those given for lymphomas and leukaemia. We feel that any evaluation of stem cell transplantation in IBD should assess the benefit of these periods of clinical remission with consequent improvement of quality of life for patients refractory to conventional therapy. Although much of the early stem cell transplantation for autoimmune diseases involved purging T lymphocytes from the graft, the current data on 145 patients in the autoimmune transplant programme does not support any advantage of such manipulation for the prevention of early relapse. 2 The immunological recovery pattern with an early CD19 and NK cell recovery, a prolonged CD4 and CD4/CD8 ratio reduction after high-dose chemotherapy has already been reported. Several authors relate this low number of CD4 cells to a persistently low level of naive CD4 + CD45RA + cells (thymus-dependent) related to thymic damage after high-dose chemotherapy. While studies in patients with established Crohn's disease have generally supported the predominance of cell-mediated immunity due to T helper 1 responses, enhanced humoral immunity appears to predominate in UC. An altered distribution of the serum immunoglobulin classes and IgG subclasses, especially in cases of active untreated IBD has been found frequently. In UC, intestinal B lymphocytes secrete increased amounts of IgG 1 compared to healthy subjects and this is reflected in the serum concentrations of total IgG and IgG subclasses. 6 Despite normal numbers of circulating lymphocytes 12 months after PBSC transplantation, deficiencies in humoral responsiveness contributed to a prolonged clinical remission of UC in our case. As normal IgG levels were reached after disease relapse, total serum IgG seemed to reflect the activity of the autoimmune disorder.
Unrelated cord blood transplantion in a Fanconi anemia patient using fludarabinebased conditioning
Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by progressive pancytopenia, congenital malformations, chromosomal instability and predisposition to the development of malignancies. Hematopoietic cell transplantation (HCT) from a matched sibling donor is the only curative approach for the hematological abnormalities associated with FA; unfortunately only 25% to 35% of FA patients have a compatible cord blood or marrow donor. 1 Successful outcome for transplantation in FA patients with non-matched sibling donors is in the range of 25-40%; graft rejection, high risk of developing graft-versus-host disease (GVHD) and regimen-related toxicities have been This finding is supported by a recent report suggesting that serum IgG levels could be used as additional disease markers for activity in UC. 7 We feel that further investigations should be carried out to determine the significance of the correlation between IgG subclasses and IBD activity.
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Oncologia Umbilical-cord blood from unrelated donors can restore and sustain hematopoietic function, with a low risk of GVHD. 3 Studies performed at FHCRC showed that sublethal doses of total body irradiation (TBI, 200 cGy) followed by potent post-transplant immunosuppression (cyclosporin A, CsA plus mycophenolate mofetil, MMF) were able to prevent GVHD and graft rejection, allowing stable mixed chimerism. Fludarabine (FLU)-based conditioning regimens, capable of intense T cell immunosuppression, have been used successfully for various non-malignant diseases, with minimal toxicity and stable and durable engraftment. 4, 5 FA patients are natural candidates for non-myeloablative transplantation, because of their cellular hypersensitivity to DNA cross-linking agents, such as cyclophosphamide (CFA) and radiotherapy.
